The Surprising Part of Tilray's Business That Drove Most of Its Growth Last Year

Axe Cap view

Tilray's Growth Comes from Distribution, but Losses Persist

Tilray’s distribution business drove revenue gains, yet its operating losses weigh heavily on investor confidence.

Tilray’s 11% revenue growth looks encouraging at first, but digging deeper reveals the growth isn’t where many expected. The distribution arm grew 21%, outpacing both cannabis and beverages, which traditionally defined the company’s appeal. This shift suggests Tilray is leaning on its pharmaceutical distribution network, CC Pharma, to stay afloat. For South African investors, the lesson is clear: growth alone isn’t enough when losses pile up. The company posted a $63 million operating loss, keeping it unprofitable and fueling uncertainty about its path to sustainability. On the JSE, this reminds me of how entities like Sasol or AngloGold Ashanti are judged not just on revenue but on consistent earnings and cash flow. Meanwhile, the rand’s volatility (USD/ZAR) could punish companies that can’t control their cost base in hard currency terms. Given Tilray’s shaky fundamentals, it’s a speculative hold at best, and more a wait-and-see. this is just our opinion and not financial advice